Naason Science CRO (Contract Research Organization) - Where the next generation of preclinical research begins!Faster, better decisions - Based on knowledge of drug discovery and outsourcing experience, building the best integrated global preclinical services with an emphasis on innovation, reliability and commitment. Naason´s various preclinical modelling platforms are customized to suite the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a tool box of state-of-the-art technologies the allow for rapid and effective testing of preclinical drug candidates. The Naason process starts from an in-depth knowledge of the demands of global pharmaceutical development. It involves combining superior knowledge of biological systems and system dynamics with the latest preclinical disease models, highlighting the comparative and translatable aspects and using this data to highlight the way forward for a particular drug or a drug development platform. The data generated from our preclinical modelling platforms is designed to provide pertinent insight and better translatability in order to allow for easier decisions made faster. Faster decision making allows a reduction in the cost of research and development. Naason Science provides the tools to study neurology, oncology, cardiovascular and metabolic therapies in a way that allows faster and better decisions. Let us show you !
Schizophrenia, Depression, AnxietyPain
Neuropathic-Chung, CCI, Visceral-Endometriosis, Bladder, Chemotherapy-induced pain, Central PainOncology
Syngenic Melanoma, Xenograph, Pancreatic Cancer, Glioblastom
Dry eye disease, AMD
NASH, DiabetesSafety & Toxicology
Mouse, rat, canine, pig, NHP, ADME PK
Larry Chong Park, PhD, co-founder and CEO of Naason Science, Inc., has worked in pharma/biotech drug discovery and development for the last 20 years. Prior to Naason Science, Larry, as the director of preclinical research, led and directed drug discovery campaigns from lead optimization through IND filing at CHDI Management/Foundation, Inc for 13 years. Working closely with academic and CRO partners, he has characterized several genetically engineered animal models of Huntington’s Disease and evaluated over 200+ lead compounds in vivo, some of which are now clinical candidates.
Prior to CHDI, Larry was a senior research scientist and group leader at Vertex Pharmaceuticals, Inc., Cambridge, MA, USA, where he led the in vivo pharmacology group in developing small molecule kinase inhibitors for CNS, oncology and immunology indications. Prior to Vertex, he led the CNS cell biology group to develop various HTS-Driven biochemical and cell-based screen assays at Galileo Pharmaceuticals, Inc, Santa Clara, CA, USA.
Larry received his BS in biology from UCLA, and his PhD in pharmacology and toxicology from University of California, Irvine. His postdoctoral research was in CNS metabolic diseases at the Burke Institute of Cornell Medical College.
150+ Years of Cumulative CRO and Preclinical Drug Development Experience located in two world class cutting-edge centers of Osong Bio-medical Science Complex in Osong and DGMIF in Daegu, South Korea.
Please do not hesitate to contact us firstname.lastname@example.org if you have any questions about our products and services.
Patrick J. Sweeney PhD, MBA >>>
Founder & COO
Jonathan E. Friedman PhD >>>
Our personal email addresses are in form firstname[at]naasonscience.com.
Kati Sweeney BBA, MSc >>>
Director of Marketing
Kyung Ho Park DVM >>>
Larry Chong Park PhD
Founder & CEO
150+ Years of Cumulative CRO and Preclinical Drug Development Experience
located in two world class cutting-edge centers of Osong Bio-medical Science Complex in Osong and DGMIF in Daegu, South Korea.
Copyright © Naason Science Inc 2019. All rights reserved.